Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient
Background: Pharmacogenomics (PGx) can provide more precision in determining causation of adverse drug reactions (ADRs) from drug-drug-gene interaction clinical application. Case Summary: Patient was an intermediate CYP2C19 metabolizer on stable therapy taking a low but therapeutic dose of sertra...
Main Authors: | Jade Nanan, Sheena Crosby, Michael J. Schuh |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2022-09-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/4890 |
Similar Items
-
High-Evidence, Actionable Phenotype Gene Distribution in a Multispecialty, Tertiary Care Clinic: Potentially Actionable Genes and a Referring Department Profile
by: Blake Bartlett, et al.
Published: (2023-06-01) -
Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
by: Michael J. Schuh, et al.
Published: (2020-05-01) -
Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients
by: Heather Randles, et al.
Published: (2019-12-01) -
Editorial: Pharmacogenomics in neglected populations
by: Mariana R. Botton, et al.
Published: (2022-11-01) -
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
by: Tereza Buchtova, et al.
Published: (2023-02-01)